Michael D Ehlers has sold BIIB and made no open-market buys since Sep 2018

Michael D. Ehlers, M.D., Ph.D., is a biopharmaceutical R&D executive and biotech entrepreneur who served as Executive Vice President, Research and Development at Biogen Inc. (BIIB), where he led global research, drug discovery, translational medicine, clinical development, regulatory sciences, and medical affairs with a focus on neurological, immunological, and rare diseases.( In this role he defined the strategic direction of Biogen’s R&D organization, significantly expanded and diversified the clinical portfolio, advanced more than 20 novel clinical candidates, and oversaw worldwide regulatory filings and approvals for Spinraza (nusinersen), the first approved treatment for spinal muscular atrophy.( As a senior corporate insider, he reported directly to the CEO and was a member of Biogen’s executive management team.(

Before joining Biogen, Ehlers held senior leadership positions at Pfizer, including Group Senior Vice President for BioTherapeutics R&D and Chief Scientific Officer for the Neuroscience and Pain Research Unit, where he built and advanced neuroscience and rare disease portfolios and brought dozens of compounds into the clinic.( Earlier in his career, he was the George Barth Geller Professor of Neurobiology and a Howard Hughes Medical Institute Investigator at Duke University Medical Center, pioneering influential studies on neuronal organelles and neurotransmitter receptor trafficking.( He is currently an Entrepreneur Partner at MPM BioImpact and CEO of Ascidian Therapeutics, following prior service as General Partner and Chief Scientific Officer at Apple Tree Partners and co‑founder of multiple RNA and immuno‑oncology companies.( Ehlers earned a B.S. in chemistry from the California Institute of Technology and M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine, and has authored over 80–100 scientific papers and received numerous awards in neurobiology, pharmacology, and neuroscience.(

Written by Perplexity from public sources.